InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,055.60
(
0.22%
)
Dow Jones
39,357.01
(
-0.36%
)
Brent Oil
81.41
(
-0.24%
)
Bitcoin
59,428.20
(
0.12%
)
Post# of 252862
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 219
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: DewDiligence post# 58746

Tuesday, 02/12/2008 7:58:45 AM

Tuesday, February 12, 2008 7:58:45 AM

Post# of 252862
Dyax Licenses Antibodies to Sanofi
Tuesday February 12, 7:40 am ET
Dyax Licenses Development, Sales Rights for Antibody Drug Candidates to Sanofi-Aventis


CAMBRIDGE, Mass. (AP) -- Pharmaceutical company Sanofi-Aventis SA has bought the worldwide development and sales rights to Dyax Corp.'s antibody drug candidates, Dyax said Tuesday.
The deal is worth up to $500 million to Dyax based on development and sales milestones. Dyax will receive $25 million in 2008 and retain profit-sharing rights.

The main antibody in the deal is DX-2240, which has therapeutic potential in numerous cancers, Dyax said.



Your World Is As BIG as You Make It!!!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up